| Size | Price | Stock |
|---|---|---|
| 5mg | $95 | In-stock |
| 10mg | $140 | In-stock |
| 25mg | $280 | In-stock |
| 50mg | $410 | In-stock |
| 100mg | $656 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-12757 |
| M.Wt: | 370.47 |
| Formula: | C20H22N2O3S |
| Purity: | >98 % |
| Solubility: | DMSO : 33.33 mg/mL (ultrasonic) |
YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC50 value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model[1][2][3].
In Vitro:YHO-13177 (0.01 to 1 μM, 96 h) reverses BCRP-mediated drug resistance and sensitivity in a concentration-dependent manner in various BCRP-transduced cancer cells[1].
YHO-13177 (0.01 to 1 μM, 96 h) decreases the expression of BCRP protein in HCT116 and HCT116/BCRP cells, or A549 and A549/SN4 cells[1].
YHO-13177 (0-0.1 μM, 96 h) reduces the side population cell ratio in HeLa cells in a concentration-dependent manner[2].
In Vivo:YHO-13177 (19.7μM, i.v., or 27.3μM, p.o., a single dose for 25 days) is converted by YHO-13351, increases the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppresses the tumor growth in an HCT116/BCRP xenograft mouse model[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.